4P 022
Alternative Names: 4P-022Latest Information Update: 07 Nov 2022
At a glance
- Originator 4P-Pharma; Oncocross
- Class Skin disorder therapies
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Systemic scleroderma
Most Recent Events
- 01 Nov 2022 Early research in Systemic scleroderma in France (unspecified route) (4P-Pharma pipeline, November 2022)
- 01 Nov 2022 Early research in Systemic scleroderma in South Korea (unspecified route) (4P-Pharma pipeline, November 2022)
- 25 Oct 2021 Oncocross and 4P-Pharma enter into a research collaboration agreement to develop an AI platform-based treatment for Systemic scleroderma